Cue Biopharma, Inc.
CUE
$0.768
-$0.0004-0.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -9.65% | 14.86% | 17.62% | 8.09% | -22.07% |
| Total Depreciation and Amortization | 245.25% | -187.59% | 1,528.28% | -96.69% | 332.74% |
| Total Amortization of Deferred Charges | -10.00% | 11.11% | 0.00% | 0.00% | -10.00% |
| Total Other Non-Cash Items | -118.15% | 266.76% | -61.96% | 2,155.37% | -97.14% |
| Change in Net Operating Assets | 29.17% | 48.67% | -804.38% | 57.65% | -363.01% |
| Cash from Operations | -19.94% | 24.65% | -2.11% | 10.71% | -40.51% |
| Capital Expenditure | -300.00% | 110.00% | 81.82% | -- | -- |
| Sale of Property, Plant, and Equipment | -98.97% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Investing | -101.02% | 1,080.00% | 81.82% | -- | -100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.10% | 0.00% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | -99.38% | -- | -100.00% | -41.99% | 3.45% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -109.49% | 1,082.10% | -142.48% | -50.77% | 4.21% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -516.43% | 121.75% | -46.96% | -21.19% | -445.03% |